Related Experiment Video
Updated: Jul 31, 2025

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
Severe hepatotoxicity during treatment with capmatinib
Carmen María Valencia Soto1, Virginia Martínez Callejo1, Adela García-Avello Fernández-Cueto1
1Pharmacy Service, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Capmatinib, a targeted therapy for metastatic non-small cell lung cancer (NSCLC), can cause severe liver injury (hepatotoxicity). Early recognition and monitoring are crucial for managing this rare but serious adverse drug reaction.
Area of Science:
- Oncology
- Pharmacology
- Hepatology
Background:
- Capmatinib is approved for metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations.
- Drug-induced liver injury (DILI) is a potential adverse drug reaction (ADR).
Related Concept Videos
Hepatic Drug Excretion: Influencing Factors
Teratogenicity
Hepatic Drug Clearance: Effect of Protein Binding
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Myocarditis III: Medical Management

